Systemic sclerosis & Raynaud's
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database
Authors' conclusion
In this first large real-world study, the effectiveness of TCZ, RTX, MMF, and CYC on FVC change in SSc-ILD patients was not statistically different.
Study context
- Population
- Radiologically confirmed SSc-ILD patients with treatment records for tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), or CYC, EUSTAR database997 treatment observations
- Participants
- 955 participants
- Exposure
- TCZ vs RTX vs MMF vs CYC
- Outcome
- Change in FVC percent predicted from baseline to follow-up
Methodological detailspost hoc, real-world registry (EUSTAR database), propensity score-based inverse probability of treatment weighting (IPTW)
- Post hoc
- Real-world registry (EUSTAR database)
- Propensity score-based IPTW
Main finding
As reported in the abstract
Change in FVC percent predicted · median follow-up 11 months (IQR, 8-14 months)
- Changes in forced vital capacity (FVC) percent predicted not significantly different in the multigroup comparison after IPTW
- P = .101
Observational data: associations, not effects.
Further findings
Stable FVC (logistic regression)
- CYC was associated with stable FVC
Change in FVC percent predicted (subgroups: combination immunosuppressants (IS), previous TCZ, RTX or conventional IS, current smokers or nonsmokers, initiating or noninitiating stage)
- Treatment differences among the 4 groups not significant in any subgroup
Original publication
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. Ann Rheum Dis. Published 1 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →